Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Assembly Biosciences announced plans to expand the clinical development of its oral entry inhibitor ABI-6250 into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The company plans to initiate a Phase 2 basket study in these cholestatic liver diseases in Q1 2027, following a constructive pre-IND meeting with the FDA.
Key figures
- Drug Name
- ABI-6250
- Phase Of Trial
- Phase 2
- Hdv phase2 start
- Q4 2026
- Pbc psc study start
- Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.